Zacks Investment Research downgraded TrovaGene Inc (NASDAQ:TROV) to Hold in a report released today.
- Updated: September 20, 2016
Just yesterday TrovaGene Inc (NASDAQ:TROV) traded -2.11% lower at $4.76. TrovaGene Inc’s 50-day moving average is $5.22 and its 200-day moving average is $5.03. The last stock price is down -7.46% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 286,022 shares of TROV traded hands, down from an average trading volume of 289,822
Previously on 08/24/2016, Zacks Investment Research released a statement about TrovaGene Inc (NASDAQ:TROV) increased the target price from $0.00 to $5.75. At the time, this indicated a possible upside of 0.10%.
Zacks Investment Research has downgraded TrovaGene Inc (NASDAQ:TROV) to Hold in a report released on 9/20/2016.
Recent Performance Chart
TrovaGene Inc has 52 week low of $2.85 and a 52 week high of $7.22 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 5 brokerages have issued a research note on the company. The average stock price target is $6.30 with 0 brokerages rating the stock a strong buy, 1 brokerage rating the stock a buy, 4 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On TrovaGene Inc (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.